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Conclusion: This study shows that both SCT and SCS have sub- 
stantial beneficial effects on HRQoL. By identifying patients 
socially isolated and by ensuring social integration of patients, 
future management of OA could lead to better health outcomes, 
especially in mental dimensions which have been consistently 
found to be impaired in OA. 
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~,im: The aim of this study was to assess the relationship 
between a recently published set of response criteria n knee OA 
and patients' global evaluation of efficacy. 
Methods: In knee OA patients (N=253) treated with Hylan G-F 20 
viscosupplementation, response rates according to patients' 
evaluation of efficacy (a "good" or "satisfactory" efficacy defin- 
ing "global responder" patients) were compared with OARSI 
response rates. OARSI knee intra-articular specific drug -propo- 
sition A and B- were studied (defining "OARSI A" or "OARSI B" 
responder patients). In these three populations of responders we 
described the absolute and relative mean changes over 9 months 
in WOMAC pain, WOMAC function and global assessment 
(patient's disease activity on a VAS). 
Results: OARSI A, OARSI B and global response rates were 
respectively 62.8%, 61.7% and 71.7%. Out of global responders, 
76.8% were OARSI A and 75.7% OARSI B responders. There 
were 87.5% and 87.9% global responders in OARSI A and B 
responders. 
Mean changes in the three responder populations were given 
below: 
OARSI A OARSI B Global 
responders 
Pain change 
- absolute (ram) - 35.6 + 14.8 
- relative (%) - 70.3 ± 20.6 
Function change 
- absolute (mm) -28.4 ± 15.7 
- relative (%) -62.7 ± 26.5 
Global assessment change 
- absolute (mm) - 41.7 + 21.4 
- relative (%) - 66.7 ± 30.0 
- 36.0 ± 14.7 - 29.6 ± 18.8 
- 70.6 ± 20.8 - 60.3 ± 32.3 
-29.0 ± 15.4 -23.3 ± 18.7 
-63.6 ± 25.4 -51.1 ± 40.6 
-41.9 ± 21.3 -35.6 ± 24.4 
- 67.0 ± 29.9 - 58.2 ± 39.5 
Conclusions: Higher mean changes in pain, function and global 
assessment are required to fulfill OARSI response criteria com- 
pared to patients' global response. Mean changes and response 
rates for knee intra-articular specific drug were similar whatever 
proposition A or B applied. 
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Bone marrow edema (BME) by magnetic resonance imaging 
(MRI) is a prominent finding of several pain syndromes. We 
hypothesized that subchondral BME coupled with information 
about the nature and location of focal cartilage defects would 
explain the conundrum of self-reported joint pain in the apparent 
absence of x-ray-defined knee osteoarthritis (OAK). A total of 
120 women grouped by self-reported pain and x-ray status (30 
per group) were identified from the Southeast Michigan Arthritis 
cohort of black-and white pre- and perimenopausal women 
(n=1053), aged 33-55, with weight bearing x-rays of both knees, 
self-reported knee joint pain and risk factors for OA. Definition of 
OAK was a Kellgren-Lawrence score of two or greater. 
Participants were evaluated using a 1.5 T (GE Sigma) scanner 
equipped with a knee surface coil. Sequences involved fast spin 
echo proton density with fat saturation sequences. Scoring for 
BME and cartilage defects were undertaken by two radiologists, 
blinded as to the x-ray OAK status and to group assignment. 
Group Pain x-ray OAK No BME No cartilage 
n=30/grp defect 
t No No 50% t7% 
2 No Yes 13% 0% 
3 Yes No 47% 20% 
4 Yes Yes 10% 0% 
Women with evidence of BME were 7 times more likely (95% 
C1=2.7,17.7) to be identified by x-ray as having OAK whereas the 
Odds ratio for BME and pain was 1.1 (95% Cl=0.5-2.5).The sum- 
mary BME in the worst knee did not account for self report of pain 
or account for the pain/x-ray OA incongruity in groups 2 and 3. 
BME is likely due to mild cellular injury, probably induced by 
micro-trauma. However, using a global measure of BME did not 
explain the dissonance between report of pain and x-ray findings. 
Further evaluation will be required to determine if comparison by 
compartment or severity is more explanatory of the dissonance. 
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THE AUSCAN OSTEOARTHRITIS (OA) HAND INDEX: USE IN 
THE EVALUATION OF HAND OA PATIENTS IN THE 
"ADVANTAGE" TRIAL 
EL R Gebal~A. B. Polls 1 , M. E. Dixon 1 , 
C. S. Skalky 3, N. Bellamy 2, 
1Merck and Co., Inc., West Point, PA 19486, USA 
2University of Queensland, Brisbane, Australia 
Method: A cohort of patients with OA of the hand was evaluated 
in a planned subgroup analysis, using AUSCAN OA Hand Index 
in a trial assessing the gastrointestinal (GI) tolerability of rofecox- 
ib (RO) and naproxen (NA) in the treatment of patients with knee, 
hip, hand, or spine OA over 12 weeks. Eligible patients were ran- 
domly assigned to treatment with RO 25 mg qd or NA 500 mg 
bid. GI tolerability, as defined by the incidence of discontinuations 
due to GI adverse experiences (AE), was the primary endpoint. 
OA efficacy was assessed by the Patient Global Assessment of 
Disease Status (PGADS), the AUSCAN OA Hand Index LK3.0S, 
and discontinuations due to lack of efficacy (LOE). 
Results: 5557 patients received RO (n=2785) or NA (n=2772). 
Baseline characteristics were similar between treatment groups. 
16.4% of patients (n=447 and 463; RO and NA respectively) 
patients identified the hand as their primary source of OA symp- 
toms and were required to complete the AUSCAN questionnaire, 
a categorical scale (Pain/Difficulty: 1=None to 5=Extreme) to 
assess three domains of hand OA (pain, stiffness, and physical 
function, comprised of 5, 1 and 9 questions, respectively). 
Patients were asked to select one pain item and one physical 
function item which they most hoped would improve. Also, all 
patients completed the PGADS, a 100 mm VAS (0=very well; 
100=very poor). 
Rotecoxib Naproxen P value 
PGADS change (mm) Hand* - 6.94 - 6.41 N S 
AUSCAN Pain Domain" - 0.28 - 0.31 N S 
AUSCAN Stiffness Domain* - 0.39 - 0.33 N S 
AUSCAN Function Domain" - 0.37 - 0.38 N S 
Discontinuations due to LOF 6.4% 6.3% N S 
GIAEDiscontinuations 5.9% 8.1% 0 . 0 0 5 
"Reported as mean change from baseline 
